Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 5.
doi: 10.1002/jpn3.70180. Online ahead of print.

Effectiveness and safety of oral vancomycin in non-primary sclerosing cholangitis paediatric inflammatory bowel disease

Silvana Ancona  1 , Laura Gianolio  1   2 , Katherine Armstrong  1 , Rosalind Rabone  1 , Victoria Merrick  1 , Paul Henderson  1   3 , David C Wilson  1   3 , Richard K Russell  1   3
Affiliations

Effectiveness and safety of oral vancomycin in non-primary sclerosing cholangitis paediatric inflammatory bowel disease

Silvana Ancona et al. J Pediatr Gastroenterol Nutr. .

Abstract

Objectives: Oral vancomycin (OV) has limited usage in paediatric inflammatory bowel disease (PIBD) with reported efficacy in primary sclerosing cholangitis (PSC-PIBD), acute severe colitis as part of quadruple-antibiotic regimen, and very early-onset IBD. This study evaluates OV effectiveness and safety as a single-agent in non-PSC PIBD.

Methods: This single-centre retrospective study included patients on OV for active disease or steroid/topical therapy dependency. Exclusion criteria were PSC diagnosis, Clostridioides difficile infection, induction treatment started <3 weeks prior, and OV as part of quadruple-antibiotic regimen. Disease activity was assessed at baseline, 1-, 3-, 6- and 12-months. OV was started at 250/125 mg (≥30/<30 kg), three or four times daily, and tapered in responders after ≥1 month.

Results: Thirty-one patients (16 males; median age 15.1 years, IQR:11.7-16.6) were included: 23 ulcerative colitis (UC), 4 IBD-unclassified (IBDU) and 4 Crohn's disease. OV dosing was 17.5 mg/kg/day (IQR: 15.3-21.6) for 4 months (IQR: 1-9). Clinical and biochemical remission was achieved or maintained in 17/31 (55%), with 15/17 reducing/stopping other treatments and two remaining on OV monotherapy. Conversely, 14/31 (45%) discontinued OV due to non-response (11/14) or intolerance (3/14), the majority (11/14) within 1 month. Responders had lower baseline clinical disease activity and platelet count (p < 0.05). At 1-month faecal calprotectin dropped from 686 to 60 μg/g in responders (p = 0.001) but remained high in nonresponders. No serious adverse events occurred.

Conclusion: OV was rapidly effective in 55% of PIBD cases, enabling 48% to reduce or stop other treatments. It proved most beneficial in mildly active UC/IBDU as an induction strategy plus a maintenance option for some, with a role in others in treatment de-escalation.

Keywords: Crohn's disease; antibiotics; inflammatory bowel disease unclassified; ulcerative colitis.

PubMed Disclaimer

References

REFERENCES

    1. Kellermayer R, Zilbauer M. The gut microbiome and the triple environmental hit concept of inflammatory bowel disease pathogenesis. J Pediatr Gastroenterol Nutr. 2020;71:589‐595. doi:10.1097/MPG.0000000000002908
    1. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39‐49.
    1. Gionchetti P. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006;12:3306‐3313.
    1. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta‐analysis. Am J Gastroenterol. 2011;106:661‐673. doi:10.1038/ajg.2011.72
    1. Segal JP, Ding NS, Worley G, et al. Systematic review with meta‐analysis: the management of chronic refractory pouchitis with an evidence‐based treatment algorithm. Aliment Pharmacol Ther. 2017;45:581‐592. doi:10.1111/apt.13905

Grants and funding

LinkOut - more resources